Acasti Pharma (ACST) Investor Presentation - Slideshow

Company Overview - Acasti Pharma is a specialty pharma company focused on rare and orphan diseases[3, 55] - The company has novel drug formulation and delivery technologies to improve clinical outcomes[3, 55] - Acasti's lead assets have been granted Orphan Drug Designation (ODD) in the US and EU, offering potential market exclusivity[3, 55] - Acasti has over 40 granted and pending patents worldwide, providing exclusivity beyond 2036[3, 55] Financial Status - Acasti had approximately $50 million in cash as of September 30, 2021, providing an operating runway of two years[3, 55] - As of December 31, 2021, Acasti Pharma Inc had 44,288,183 common shares[52] - As of December 31, 2021, Acasti Pharma Inc market cap was USD $55.8M[52] Drug Candidates & Market Potential - The estimated addressable market in the US alone for GTX-104, GTX-102, and GTX-101 is $2 billion[3, 55] - GTX-104 targets Subarachnoid Hemorrhage (SAH), with an addressable market of over $300 million in the US[3, 8] - GTX-102 targets Ataxia-Telangiectasia (A-T), affecting an estimated 4,300 patients in the US, with a potential addressable market of $150 million[30] - GTX-101 targets Postherpetic Neuralgia (PHN), with an estimated addressable market of ~$400 million in the US[45]